Lluís Puig Sanz investigador espanyol
Puig Sanz, Lluís
Puig, Lluís
Puig Sanz, Lluís 1959-
VIAF ID: 53969739 (Personal)
Permalink: http://viaf.org/viaf/53969739
Preferred Forms
- 100 0 _ ‡a Lluís Puig Sanz ‡c investigador espanyol
-
- 100 1 _ ‡a Puig Sanz, Lluís
- 100 1 _ ‡a Puig Sanz, Lluís
-
- 100 1 _ ‡a Puig Sanz, Lluís ‡d 1959-
- 100 1 _ ‡a Puig, Lluís
- 100 1 _ ‡a Puig, Lluís
4xx's: Alternate Name Forms (25)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Acné | |
Adverse reactions to biologics | |
Atlas clinicopatológico en dermatología | |
Atlas de infecciones de la piel. | |
Cien preguntas clave en psoriasis | |
Consultas urgentes en dermatología | |
Dermatitis atópica y "S. aureus", implicaciones terapéuticas | |
Dermatosis ampollosas autoinmunes : avances recientes | |
Dermatosis infecciosas y exógenas | |
Dermofix : casos clínicos | |
Un Dia al parc | |
Diagnóstico y factores desencadenantes | |
Eczema : fisiopatía, diagnóstico y tratamiento | |
Estudio de bases moleculares adicionales que definan la eficacia de vismodegib y fenómenos de resistencia en pacientes con carcinoma basocelular localmente avanzado y/o metastásico mediante la recogida de biopsias ctáneas seriadas durante el tratatmiento con este fármaco | |
Factores inmunológicos y psicológicos y efecto del tratamiento en pacientes con vitiligo | |
Focus en... psoriasis : risankizumab | |
Hemoterapia en hematología clínica | |
Homenatge a Esteve Albert i Corp 1914-1995 | |
Manual de Cirugía Dermatológica | |
Metotrexato y psoriasis | |
MIR 3 : curso de actualización en dermatología para médicos internos y residentes | |
Modulación farmacológica y dietética del metabolismo del ácido araquidónico implicaciones en la psoriasis | |
[Non-congenital smooth muscle hamartoma: 3 cases] | |
Obesity and psoriasis: body weight and body mass index influence the response to biological treatment | |
Of APACHEs and PALEFACEs | |
Onicomicosis | |
PASI90 response: the new standard in therapeutic efficacy for psoriasis | |
Pathogen inactivation of platelet concentrates. | |
The pathogenesis and genetics of psoriasis | |
Periungual acral fibrokeratoma: surgical excision using a banner flap | |
Petechial glove and sock syndrome caused by parvovirus B19 | |
Pharmacodynamic interaction with phototoxic plants during PUVA therapy | |
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey | |
El pie : higiene y patología | |
La Piel y el sistema nervioso | |
Pigmented dermatofibrosarcoma protuberans (Bednar's tumor) | |
Pityriasis lichenoides chronica induced by infliximab, with response to methotrexate | |
Primary anetoderma associated with primary Sjögren syndrome and anticardiolipin antibodies | |
Primary neuroendocrine carcinoma of the skin expresses tyrosinase mRNA: detection by a specific nested PCR technique | |
Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma | |
Progression pathways of squamous cell carcinoma associated with actinic damage: from cancer field to actinic keratosis and invasive squamous cell carcinoma | |
Proliferating trichilemmal tumour: p53 immunoreactivity in association with p27Kip1 over-expression indicates a low-grade carcinoma profile | |
Propranolol-resistant infantile hemangioma successfully treated with sirolimus | |
Protocolos de actuación en micosis superficiales y de las uñas | |
Pseudoscleroderma secondary to phytonadione | |
Pyoderma gangrenosum in association with erythema elevatum diutinum: report of two cases | |
Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments | |
Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. | |
Reiter's syndrome-like pattern in AIDS-associated psoriasiform dermatitis | |
Response to: "On Cardiovascular Risk Estimation in Patients With Psoriasis: The REGICOR and SCORE Scales" | |
Reversal of nonstructural protein 3-specific CD4(+) T cell dysfunction in patients with persistent hepatitis C virus infection | |
Risk variants for psoriasis vulgaris in a large case–control collection and association with clinical subphenotypes | |
The safety of brodalumab for the treatment of psoriasis | |
The safety of ixekizumab in psoriasis drug therapy | |
Scalp psoriasis: European consensus on grading and treatment algorithm | |
Secukinumab: evidencia vs experiencia | |
Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. | |
Shortcomings of PASI75 and practical calculation of PASI area component | |
Significant weight loss improves and prevents psoriasis and psoriatic arthritis in obese patients: a Critically Appraised Topic and a call to action | |
Therapeutic targeting of the IL-13 pathway in skin inflammation | |
Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature | |
Thrombotic thrombocytopenic purpura and pregnancy: a review of ten cases. | |
Topical tacrolimus 0.1% ointment | |
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). | |
Transient monoclonal gammopathy associated with cyclosporin treatment of psoriasis | |
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial | |
Tratamiento de la dermatitis atópica : nuevas opciones | |
Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review | |
Treatment of meralgia paraesthetica with topical capsaicin | |
[Treatment of moderate-severe psoriasis with etanercept in patients with chronic human immunodeficiency virus infection] | |
Triple paradoxical reaction due to adalimumab. | |
Ustekinumab in clinical practice: response depends on dose and previous treatment | |
Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review | |
Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase III clinical trial | |
Validation of the Spanish Acne Severity Scale (Escala de Gravedad del Acné Española--EGAE). | |
[Validation of the Spanish version of the Psoriasis Disability Index questionnaire in assessing the quality of life of patients with moderate-severe psoriasis] | |
[Validity of a telephone survey for determining the prevalence of atopic dermatitis and its seasonal variation in Spain] | |
The Value of Achieving Complete or Near Complete Resolution of Psoriasis. | |
Veinte preguntas en dermatitis atópica | |
Verrucous hemangioma | |
Von Recklinghausen neurofibromatosis with carcinoid tumor and submucous leiomyomas of the duodenum | |
[Which patient is a candidate for treatment with efalizumab and why?]. |